<DOC>
	<DOCNO>NCT00700271</DOCNO>
	<brief_summary>This study multicenter , randomize , PROBE-type ( prospective , randomize , open label , blind end-point ) study 12 week duration comprise four visit , carry patient essential arterial hypertension control four week treatment amlodipine 5 mg alone .</brief_summary>
	<brief_title>Efficacy Combination Amlodipine/Valsartan 24H Blood Pressure Control With One Nocturnal Diurnal Intake Day</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Age &gt; = 18 year Essential uncontrolled naive hypertensive patient ( SBP â‰¥= 140 mmHG , DBP &gt; /=90 mm Hg , SBP &gt; = 130 mmHg , DBP &gt; = 80 mmHg diabetes renal impairment ) except patient treated amlodipine , intolerant ARBs and/or calcium channel blocker . Severe hypertension : SBP &gt; = 180 mmHg , DBP &gt; = 110mmHg Pregnancy Allergia ARBs and/or calcium channel blocker Antihypertensive tritherapy V1 History heart failure , pectoris angina , stroke , myocardial infarction Diabetes type I Renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>ambulatory blood pressure monitoring</keyword>
</DOC>